🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

John N. Allan

Cornell University

ORCID: 0000-0002-2088-0899

Also affiliated with Weill Cornell Medicine

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials”.

Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials

British Journal of Haematology(2021)10.1111/bjh.17984
N/A
2.2DataRank · unranked
64 citations

Tait D. Shanafelt, Adrian Wiestner, Carol Moreno, Susan O’Brien, Jianling Li +4 more

An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL

Blood Advances(2024)10.1182/bloodadvances.2023012142
N/A
0.569DataRank · unranked
18 citations

John N. Allan, Dan James, Helen Bridge, Miguel Miranda, Alan SM Yong +6 more

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Blood(2021)10.1182/blood.2021011841
N/A
0DataRank · unranked
70 citations

Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander Coltoff, Matthew S. Davids +47 more

Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies

Journal of Clinical Investigation(2023)10.1172/jci170169
N/A
0DataRank · unranked
43 citations

Fen Zhu, Olga Dashevsky, Rin Mizuno, Jolin Xiao Hui Lai, Liam Hackett +19 more

Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

Blood(2023)10.1182/blood-2023-187128
N/A
0DataRank · unranked
39 citations

William G. Wierda, Paul M. Barr, Thomas J. Kipps, Tanya Siddiqi, John N. Allan +6 more

Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study

Blood Advances(2024)10.1182/bloodadvances.2023011569
N/A
0DataRank · unranked
11 citations

Jenna Voutsinas, Bita Fakhri, Sirin Khajavian, Stephen E. Spurgeon, Deborah M. Stephens +30 more

Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL

Blood Cancer Journal(2025)10.1038/s41408-025-01236-6
N/A
0DataRank · unranked
12 citations

Ying Huang, Sarah Miller, John N. Allan, Seema A. Bhat, David A. Bond +40 more

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Blood(2020)10.1182/blood.2020006965
N/A
0DataRank · unranked
318 citations

Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori A. Leslie, John M. Pagel +57 more

Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry

Blood Cancer Journal(2025)10.1038/s41408-024-01207-3
N/A
0DataRank · unranked
3 citations

Chantal E. McCabe, Laura A. Bruins, Daniel O’Brien, Sochilt Brown, Renee C. Tschumper +16 more

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3815
N/A
0DataRank · unranked
116 citations

Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna, Danielle M. Brander +49 more